Overview

Examination of Plasma Concentrations and Safety in Chronic Kidney Disease Patients Undergoing Hemodialysis

Status:
Completed
Trial end date:
2013-06-26
Target enrollment:
Participant gender:
Summary
This study is to assess the safety, tolerability, plasma concentration and pharmacodynamics of ASP7991 after oral administration to patients with chronic kidney disease undergoing hemodialysis.
Phase:
Phase 1
Details
Lead Sponsor:
Astellas Pharma Inc
Treatments:
ASP7991